The obesity drug Wegovy, developed by Novo Nordisk, could reach double blockbuster status as soon as next year, estimates an analysis from Danske Bank, reports media PLX.AI.
A blockbuster drug is industry terminology for a drug exceeding USD 1bn in sales annually. This latest estimation from Danske Bank is almost twice its earlier expectations for the medicine.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.